Proteomics

Dataset Information

0

Proteomic analysis of liver cytosol and mitochondria of apoE-KO mice treated with TUG-891.


ABSTRACT: ApoE-KO mice were treated with FFAR4 agonist TUG-891 for 16 weeks. Protein abundance changes in relation to untreated control were measured in liver samples fractionated to cytosol and mitochondria by SWATH-MS.

INSTRUMENT(S): TripleTOF 6600

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Liver

DISEASE(S): Non-alcoholic Fatty Liver Disease

SUBMITTER: Maciej Suski  

LAB HEAD: Rafal Olszanecki

PROVIDER: PXD028535 | Pride | 2024-08-09

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
20210909_082144_Ania_apoE_liver_cytosol_TUG.sne Other
20210909_094538_Ania_apoE_liver_mitochondria_TUG.sne Other
C382T.wiff Wiff
C382T.wiff.scan Wiff
C384K.wiff Wiff
Items per page:
1 - 5 of 64
altmetric image

Publications

The Influence of the FFAR4 Agonist TUG-891 on Liver Steatosis in ApoE-Knockout Mice.

Kiepura Anna A   Suski Maciej M   Stachyra Kamila K   Kuś Katarzyna K   Czepiel Klaudia K   Wiśniewska Anna A   Ulatowska-Białas Magdalena M   Olszanecki Rafał R  

Cardiovascular drugs and therapy 20230127 4


<h4>Background</h4>Nonalcoholic fatty liver disease (NAFLD) constitutes an independent risk factor for the development of coronary heart disease. Low-grade inflammation has been shown to play an important role in the development of atherosclerosis and NAFLD. Free fatty acid receptor 4 (FFAR4/GPR120), which is involved in damping inflammatory reactions, may represent a promising target for the treatment of inflammatory diseases. Our objective was to evaluate the effect of TUG-891, the synthetic a  ...[more]

Similar Datasets

2023-03-11 | PXD028547 | Pride
2023-07-20 | PXD036521 | Pride
2023-03-11 | PXD034591 | Pride
2024-07-05 | PXD033008 | Pride
2024-07-05 | PXD032976 | Pride
2024-07-05 | PXD032833 | Pride
2021-06-24 | PXD018063 | Pride
2021-06-24 | PXD018039 | Pride
2022-08-22 | PXD031174 | Pride
2023-07-03 | PXD028281 | Pride